Report of Foreign Issuer (6-k)
January 09 2017 - 9:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of January 2017
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
Exhibit |
Title |
|
|
99.1 |
News Release Dated January 9, 2017 - Medicure Provides Apicore Secured Loan to Replace Knight Loan |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: January 9, 2017 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Provides Apicore Secured Loan to Replace Knight
Loan
Acquires additional common shares
in Apicore
WINNIPEG, Jan. 9, 2017 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce
that it has provided a secured loan in the amount of US$9.8 million to Apicore Inc. ("Apicore") allowing for the repayment
of Apicore's existing debt with Knight Therapeutics Inc. (TSX: GUD) and Sanders Morris Harris Inc. The loan bears interest
at 12% per annum, matures on December 30, 2020 and is secured by a charge over the U.S. assets of Apicore. Funding to provide
this loan was previously obtained from Crown Capital Fund IV, LP, an investment fund managed by Crown Capital Partners Inc. ("Crown")
(TSX:CRN), in which Crown holds a 40% interest, and the Ontario Pension Board, a limited partner in Crown's funds, as previously
announced on November 18, 2016.
The loan constitutes a "related party transaction"
under Multilateral Instrument 61-101 ("MI 61-101") Protection of Minority Security Holders in Special Transactions
and absent available exemptions would trigger the requirement for a formal valuation and minority shareholder approval of the transaction.
The Company has relied on the exemptions from these requirements contained in Sections 5.5(a) and 5.7(a) of MI 61-101 on the basis
that the fair market value pertaining to the transaction does not exceed 25% of the Company's market capitalization, calculated
in accordance with MI 61-101. A material change report in respect of the loan will be filed as required, but was not filed 21 days
in advance of the closing of the loan due to the Company's desire to complete the loan as quickly as possible. The loan was approved
by the Board of Directors of the Company.
Additionally, Medicure has acquired an additional 112,500
Class E common shares of Apicore, representing approximately 1% of Apicore, for US$549,000 from a former employee of Apicore and
former members of Apicore's Board of Directors. These shares were issued as a result of the exercise of stock options held
in Apicore by these individuals and purchased by Medicure at a pre specified price in accordance with Apicore's stock option plan
and Medicure's option rights. Medicure currently owns approximately 61% of Apicore on a fully diluted basis and continues to hold
option rights until July 3, 2017 to acquire additional shares in Apicore.
About Apicore
Apicore is a private, New Jersey based developer and manufacturer
of specialty Active Pharmaceutical Ingredients ("APIs") and pharmaceuticals, including over 15 Abbreviated New Drug Applications
("ANDAs"), one of which, is partnered with Medicure. Apicore manufactures over 100 different API's, including over
35 for which Drug Master Files have been submitted to the FDA and 12 that are approved for commercial sale in the U.S. by customers
of Apicore. Apicore specializes in the manufacture of difficult to synthesize, high value and other niche API's for many
U.S. and international generic and branded pharmaceutical companies. Apicore has 2 FDA-approved facilities. In the U.S., the
Somerset, New Jersey facility can produce a few grams up to 200 kg volumes and in India, the Vadodara, Gujarat facility can produce
a few kilograms up to 60 metric tons yearly. Both facilities are equipped with state-of-the-art analytical and research capabilities.
For more information, please visit Apicore online at www.apicore.com.
About Medicure
Medicure is a specialty pharmaceutical company focused on
the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States,
where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE Medicure Inc.
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 08:00e 09-JAN-17
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Apr 2023 to Apr 2024